Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

OptiBiotix Health receives line extension to European regulatory sign-off

"This line extension will help us convert the commercial opportunities we are working on into distribution agreements," said Dr Fred Narbel, managing director of OptiBiotix's prebiotics division

OptiBiotix Health PLC (LON:OPTI) has received European regulatory sign-off for the unflavoured version of SlimBiome Medical.

The CE Mark provides a product line extension for the firm's weight loss sachets after initial approval last November.

It allows the company to offer the 'plain' version of the line with natural flavour boosters for "minimal" additional expenditure.

The combination also provides a cost saving element as OptiBiotix now doesn’t have to register new flavours for individual regulatory sign-off.

“This line extension will help us convert the commercial opportunities we are working on into distribution agreements," said Dr Fred Narbel, managing director of OptiBiotix's prebiotics division.

As well as developing weight loss products, the AIM-listed sciences company has created compounds to tackle high cholesterol, diabetes and for use in skin care.

Its focus is controlling the interactions of human microbiome, an ecosystem of bacteria which resides in the gut and on the skin.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK